Fast-paced Momentum Stock Diversified Healthcare (DHC) Is Still Trading at a Bargain
Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves ahead of their future growth potential. In such a situation, investors find themselves loaded up on expensive shares with limited to no upside or even a downside. So, going all-in on momentum could be risky at times.
It could be safer to invest in bargain stocks that have been witnessing price momentum recently. While the Zacks Momentum Style Score (part of the Zacks Style Scores system), which pays close attention to trends in a stock's price or earnings, is pretty useful in identifying great momentum stocks, our 'Fast-Paced Momentum at a Bargain' screen comes handy in spotting fast-moving stocks that are still attractively priced.
Diversified Healthcare (DHC) is one of the several great candidates that made it through the screen. While there are numerous reasons why this stock is a great choice, here are the most vital ones:
A dash of recent price momentum reflects growing interest of investors in a stock. With a four-week price change of 4.7%, the stock of this residential care real estate investment trust is certainly well-positioned in this regard.
While any stock can see a spike in price for a short period, it takes a real momentum player to deliver positive returns for a longer time frame. DHC meets this criterion too, as the stock gained 71.5% over the past 12 weeks.
Moreover, the momentum for DHC is fast paced, as the stock currently has a beta of 2.45. This indicates that the stock moves 145% higher than the market in either direction.
Given this price performance, it is no surprise that DHC has a Momentum Score of B, which indicates that this is the right time to enter the stock to take advantage of the momentum with the highest probability of success.
In addition to a favorable Momentum Score, an upward trend in earnings estimate revisions has helped DHC earn a Zacks Rank #2 (Buy). Our research shows that the momentum-effect is quite strong among Zacks Rank #1 and #2 stocks. That's because as covering analysts raise their earnings estimates for a stock, more and more investors take an interest in it, helping its price race to keep up. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Most importantly, despite possessing fast-paced momentum features, DHC is trading at a reasonable valuation. In terms of Price-to-Sales ratio, which is considered as one of the best valuation metrics, the stock looks quite cheap now. DHC is currently trading at 0.57 times its sales. In other words, investors need to pay only 57 cents for each dollar of sales.
So, DHC appears to have plenty of room to run, and that too at a fast pace.
In addition to DHC, there are several other stocks that currently pass through our 'Fast-Paced Momentum at a Bargain' screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Diversified Healthcare Trust (DHC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Effettua l'accesso per consultare il tuo portafoglio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
JD.com, Inc. (JD) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest close session, Inc. (JD) was down 1.25% at $31.64. This change lagged the S&P 500's 0.32% gain on the day. Meanwhile, the Dow gained 0.53%, and the Nasdaq, a tech-heavy index, added 0.26%. Shares of the company witnessed a loss of 3.41% over the previous month, trailing the performance of the Retail-Wholesale sector with its gain of 3.84%, and the S&P 500's gain of 4.51%. The investment community will be closely monitoring the performance of Inc. in its forthcoming earnings report. In that report, analysts expect Inc. to post earnings of $0.5 per share. This would mark a year-over-year decline of 61.24%. Our most recent consensus estimate is calling for quarterly revenue of $47.56 billion, up 18.61% from the year-ago period. For the annual period, the Zacks Consensus Estimates anticipate earnings of $2.48 per share and a revenue of $180.25 billion, signifying shifts of -41.78% and +12.13%, respectively, from the last year. Any recent changes to analyst estimates for Inc. should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 39.49% lower. As of now, Inc. holds a Zacks Rank of #5 (Strong Sell). In terms of valuation, Inc. is presently being traded at a Forward P/E ratio of 12.93. This denotes a discount relative to the industry average Forward P/E of 21.64. We can additionally observe that JD currently boasts a PEG ratio of 3.81. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Internet - Commerce industry had an average PEG ratio of 1.63 as trading concluded yesterday. The Internet - Commerce industry is part of the Retail-Wholesale sector. This group has a Zacks Industry Rank of 69, putting it in the top 28% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize to follow all of these stock-moving metrics, and more, in the coming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (JD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
4 hours ago
- Yahoo
Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
Bristol Myers Squibb (BMY) closed at $47.17 in the latest trading session, marking a +1.59% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.32%. At the same time, the Dow added 0.53%, and the tech-heavy Nasdaq gained 0.26%. Shares of the biopharmaceutical company witnessed a loss of 1.69% over the previous month, beating the performance of the Medical sector with its loss of 3.4%, and underperforming the S&P 500's gain of 4.51%. Market participants will be closely following the financial results of Bristol Myers Squibb in its upcoming release. The company plans to announce its earnings on July 31, 2025. On that day, Bristol Myers Squibb is projected to report earnings of $1.33 per share, which would represent a year-over-year decline of 35.75%. Simultaneously, our latest consensus estimate expects the revenue to be $11.33 billion, showing a 7.15% drop compared to the year-ago quarter. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $6.48 per share and revenue of $46.29 billion, indicating changes of +463.48% and -4.16%, respectively, compared to the previous year. Investors might also notice recent changes to analyst estimates for Bristol Myers Squibb. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 4.88% fall in the Zacks Consensus EPS estimate. Bristol Myers Squibb is currently a Zacks Rank #3 (Hold). With respect to valuation, Bristol Myers Squibb is currently being traded at a Forward P/E ratio of 7.17. This indicates a discount in contrast to its industry's Forward P/E of 17.83. It is also worth noting that BMY currently has a PEG ratio of 2.39. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Biomedical and Genetics industry had an average PEG ratio of 1.53 as trading concluded yesterday. The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 83, this industry ranks in the top 34% of all industries, numbering over 250. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Home BancShares (HOMB) Meets Q2 Earnings Estimates
Home BancShares (HOMB) came out with quarterly earnings of $0.58 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.52 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this bank holding company would post earnings of $0.54 per share when it actually produced earnings of $0.56, delivering a surprise of +3.7%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Home BancShares, which belongs to the Zacks Banks - Southeast industry, posted revenues of $271.03 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.99%. This compares to year-ago revenues of $254.6 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Home BancShares shares have added about 0.7% since the beginning of the year versus the S&P 500's gain of 6.2%. What's Next for Home BancShares? While Home BancShares has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Home BancShares was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.57 on $263.9 million in revenues for the coming quarter and $2.29 on $1.05 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - Southeast is currently in the top 25% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Third Coast Bancshares, Inc. (TCBX), another stock in the same industry, has yet to report results for the quarter ended June 2025. The results are expected to be released on July 23. This company is expected to post quarterly earnings of $0.75 per share in its upcoming report, which represents a year-over-year change of +19.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Third Coast Bancshares, Inc.'s revenues are expected to be $46.89 million, up 12.3% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Home BancShares, Inc. (HOMB) : Free Stock Analysis Report Third Coast Bancshares, Inc. (TCBX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
